# Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Using Psychoactive Substances > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/monoamine-oxidase-inhibitors-drug-interactions-safety/ > **Published:** 2026-04-27T08:01:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:56:56-04:00 > **Clinical Summary:** Explore monoamine oxidase inhibitors drug interactions and safety in patients using psychoactive substances, with insights on substance use disorder treatment. --- CED Clinical Relevance  #94High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic DepressionMaoiCannabisDrug InteractionsTreatment-Resistant Journal CNS drugs Study Type [Randomized Trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/) Population Human participants Why This Matters This comprehensive review addresses a critical clinical gap where patients with treatment-resistant depression and comorbid [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) are often denied MAOI therapy due to theoretical interaction concerns. With cannabis increasingly used by psychiatric patients, understanding actual versus perceived risks with MAOIs becomes essential for optimal treatment outcomes. Clinical Summary This narrative review synthesized 219 publications examining MAOI use in patients with [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/), including interactions and treatment efficacy data. The analysis encompassed 20 RCTs, 18 non-randomized trials, 32 observational studies, and 56 case reports. The review found that while theoretical drug interactions exist between MAOIs and various psychoactive substances including cannabis, actual clinical reports of serious adverse events are relatively rare. Most documented interactions involved stimulants and certain serotonergic compounds, with cannabis-MAOI interactions appearing less problematic than often assumed. Dr. Caplan’s Take “I’ve seen too many patients with treatment-resistant depression denied potentially life-saving MAOI therapy simply because they use cannabis or have addiction histories. This review suggests our risk-benefit calculations may be overly conservative, particularly for cannabis users.” Clinical Perspective 🧠 Clinicians should consider individual risk stratification rather than blanket contraindications when evaluating MAOI therapy for patients with substance use histories. [Cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) alone should not automatically preclude MAOI consideration, though careful monitoring and [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/) about all substance interactions remain essential. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Safety%20and%20Efficacy%20of%20Monoamine%20Oxidase%20Inhibitors%20in%20Patients%20Who%20Use%20Psychoac...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41546846/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41546846/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Safety%20and%20Efficacy%20of%20Monoamine%20Oxidase%20Inhibitors%20in%20Patients%20Who%20Use%20Psychoac...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41546846/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41546846/](https://pubmed.ncbi.nlm.nih.gov/41546846/) Table of Contents - [FAQ](#FAQ)[Are MAOIs safe to prescribe in patients with substance use disorders?](#Are_MAOIs_safe_to_prescribe_in_patients_with_substance_use_disorders) - [Can patients taking MAOIs safely use cannabis?](#Can_patients_taking_MAOIs_safely_use_cannabis) - [What are the main drug interaction concerns when combining MAOIs with psychoactive substances?](#What_are_the_main_drug_interaction_concerns_when_combining_MAOIs_with_psychoactive_substances) - [Can MAOIs be used as treatment for substance use disorders themselves?](#Can_MAOIs_be_used_as_treatment_for_substance_use_disorders_themselves) - [What monitoring is required when prescribing MAOIs to patients with substance use disorders?](#What_monitoring_is_required_when_prescribing_MAOIs_to_patients_with_substance_use_disorders) - [Related](#Related) ## FAQ #### Are MAOIs safe to prescribe in patients with substance use disorders? While MAOIs are rarely prescribed in patients with SUDs due to safety concerns, this comprehensive review of 219 publications suggests they may be safer than previously thought. The evidence indicates that with proper monitoring and patient selection, MAOIs can be used in patients with comorbid substance use disorders, though careful consideration of potential drug interactions is essential. #### Can patients taking MAOIs safely use cannabis? Based on the available evidence, cannabis use with MAOIs appears to have a relatively low risk profile compared to other psychoactive substances. However, patients should be counseled about potential interactions and monitored closely, as individual responses may vary and the research remains limited. #### What are the main drug interaction concerns when combining MAOIs with psychoactive substances? The primary concerns involve substances that affect serotonin, norepinephrine, or dopamine systems, which could lead to dangerous hypertensive crises or serotonin syndrome. Stimulants, certain opioids, and serotonergic drugs pose the highest risk, while some substances like cannabis appear to have lower interaction potential. #### Can MAOIs be used as treatment for substance use disorders themselves? Emerging evidence from multiple study types suggests MAOIs may have therapeutic potential for treating certain SUDs, particularly when combined with treatment-resistant depression. However, more research is needed to establish clear efficacy and safety protocols for this indication. #### What monitoring is required when prescribing MAOIs to patients with substance use disorders? Enhanced monitoring should include regular blood pressure checks, assessment of substance use patterns, and patient education about dietary restrictions and drug interactions. Close collaboration with addiction specialists and frequent follow-up visits are recommended to ensure patient safety and treatment adherence. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41546846/”, “about”: “cns drugs randomized trial safety efficacy”, “isPartOf”: “CNS drugs”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Using Psychoactive Substances](https://cedclinic.com/monoamine-oxidase-inhibitors-drug-interactions-safety/) A detailed review of MAOI safety and efficacy in patients who use psychoactive substances, focusing on drug interactions and clinical outcomes. [Read More](https://cedclinic.com/monoamine-oxidase-inhibitors-drug-interactions-safety/) [Cannabis Use Disorder Strongly Linked to Major Depression, New Review Finds](https://cedclinic.com/cannabis-use-disorder-strongly-linked-to-major-depression-new-review-finds/) This review explores the connection between [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and major depression, highlighting implications for psychiatric treatment. [Explore Findings](https://cedclinic.com/cannabis-use-disorder-strongly-linked-to-major-depression-new-review-finds/) [Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) Comparative analysis of cannabis use disorder and other substance use disorders, providing insights into treatment challenges and outcomes. [Learn More](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).